Original ResearchPublished 6 May 2026Real-world effectiveness and safety of tildrakizumab in Japanese patients with psoriasis: a single-center 52-week observational studyDaisuke Watabe · Kanako Tsunoda · Akemi Hamabata · Maki Goto · Wakako Yoshioka · Hiroo AmanoJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2026.16442
Letter to the EditorPublished 17 November 2025Changes in biologic treatment patterns for psoriasis before and after the COVID-19 pandemic in Japan; a single center retrospective studyNatsumi Ikumi · Hideki FujitaJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2025.15613
